公开(公告)号：US08974837B2

公开(公告)日：2015-03-10

申请号：US13427334

申请日：2012-03-22

Applicant: Hyeong Kyu Lee ,  Sei Ryang Oh ,  Kyung Seop Ahn ,  Sang Ku Lee ,  Joong Ku Lee ,  Ok Kyoung Kwon ,  Doo Young Kim ,  Hyouk Joung ,  Gui Hua Quan ,  Mi Jin Kim ,  Bo Young Park

Inventor： Hyeong Kyu Lee ,  Sei Ryang Oh ,  Kyung Seop Ahn ,  Sang Ku Lee ,  Joong Ku Lee ,  Ok Kyoung Kwon ,  Doo Young Kim ,  Hyouk Joung ,  Gui Hua Quan ,  Mi Jin Kim ,  Bo Young Park

IPC: A61K36/00 ,  A61K36/185 ,  A23L1/30 ,  A61K31/35 ,  A61K31/352 ,  A61K36/68 ,  A61K36/80 ,  C07H17/04

CPC classification number: A61K36/185 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/35 ,  A61K31/352 ,  A61K36/68 ,  A61K36/80 ,  C07H17/04 ,  A23V2250/21 ,  A23V2200/324 ,  A23V2200/304

Abstract: The present invention relates to a composition comprising an extract of Pseudolysimachion genus plant, and the catalpol derivatives isolated therefrom having anti-inflammatory, anti-allergic and anti-asthmatic activity. The extract of Pseudolysimachion genus plant and the catalpol derivatives isolated therefrom shows potent suppressing effect on elevated IgE, IL-4 and IL-13 levels and eosinophilia in the plasma and BALF, and mucus overproduction in the lung tissues in an OVA-induced asthmatic mouse model. Therefore, it can be used as the therapeutics or functional health food for treating and preventing inflammatory, allergic and asthmatic disease.

Abstract translation: 本发明涉及包含假单胞菌属植物提取物和从其中分离出的具有抗炎，抗过敏和抗哮喘活性的梓醇衍生物的组合物。 假单胞菌属植物的提取物和从其中分离的梓醇衍生物显示出对OVA诱导的哮喘小鼠肺组织中升高的IgE，IL-4和IL-13水平以及血浆和BALF中的嗜酸性粒细胞增多和粘液过度产生的有效抑制作用 模型。 因此，它可以用作用于治疗和预防炎性，过敏性和哮喘性疾病的治疗剂或功能性保健食品。

公开(公告)号：US08299049B2

公开(公告)日：2012-10-30

申请号：US12626553

申请日：2009-11-25

Applicant: Hyeong-Kyu Lee ,  Sei-Ryang Oh ,  Kyungseop Ahn ,  Joongku Lee ,  Sangku Lee ,  Ho-Jae Lee ,  Doo-Young Kim ,  Jung-Hee Kim ,  Eun-Ah Kim ,  Soon-Ja Choi ,  Soo Hyun Kim ,  Jung Weon Lee ,  Su-Yong Choi

Inventor： Hyeong-Kyu Lee ,  Sei-Ryang Oh ,  Kyungseop Ahn ,  Joongku Lee ,  Sangku Lee ,  Ho-Jae Lee ,  Doo-Young Kim ,  Jung-Hee Kim ,  Eun-Ah Kim ,  Soon-Ja Choi ,  Soo Hyun Kim ,  Jung Weon Lee ,  Su-Yong Choi

IPC: A61K31/56

CPC classification number: A61K36/185 ,  A23L33/105

Abstract: The present invention relates to an anoikis-inducing agent comprising a Tiarella polyphylla extract, a tiarellic acid compound isolated therefrom or a pharmaceutically acceptable salt thereof, which is specific to cancer cells expressing a tumor-associated antigen L6 or a homolog thereof. The Tiarella polyphylla extract, the tiarellic acid compound isolated therefrom or pharmaceutically acceptable salt thereof of the present invention leads to loss of cell adhesion to reduce cancer cell proliferation and exhibits the effect of inducing cell death in cancer cells expressing a tumor-associated antigen L6 or a homolog thereof, thereby being used for preventing and treating cancer diseases due to a tumor-associated antigen L6 or a homolog thereof.

Abstract translation: 本发明涉及一种脱氧诱导剂，其包含与其分离的天竺葵多酚提取物，从其分离的噻托溴酸化合物或其药学上可接受的盐，其对表达肿瘤相关抗原L6的癌细胞或其同源物是特异性的。 本发明的天竺葵多酚提取物，从其分离的噻托溴酸化合物或其药学上可接受的盐导致细胞粘附丧失，以减少癌细胞增殖，并表现出在表达肿瘤相关抗原L6的癌细胞中诱导细胞死亡的作用 其同系物，因此用于预防和治疗由于肿瘤相关抗原L6或其同源物引起的癌症。

公开(公告)号：US20120184499A1

公开(公告)日：2012-07-19

申请号：US13427352

申请日：2012-03-22

Applicant: Hyeong Kyu LEE ,  Sei Ryang-Oh ,  Kyung Seop AHN ,  Sang Ku LEE ,  Joong Ku LEE ,  Ok Kyoung KWON ,  Doo Young KIM ,  Hyouk JOUNG ,  Gui Hua QUAN ,  Mi Jin KIM ,  Bo Young PARK

Inventor： Hyeong Kyu LEE ,  Sei Ryang-Oh ,  Kyung Seop AHN ,  Sang Ku LEE ,  Joong Ku LEE ,  Ok Kyoung KWON ,  Doo Young KIM ,  Hyouk JOUNG ,  Gui Hua QUAN ,  Mi Jin KIM ,  Bo Young PARK

IPC: A61K31/7048 ,  A61P11/06 ,  A61P29/00 ,  A61P37/08

CPC classification number: A61K31/7048 ,  A61K9/2059 ,  A61K9/4866

Abstract: The present invention relates to a composition comprising an extract of Pseudolysimachion genus plant, and the catalpol derivatives isolated therefrom having anti-inflammatory, anti-allergic and anti-asthmatic activity. The extract of Pseudolysimachion genus plant and the catalpol derivatives isolated therefrom shows potent suppressing effect on elevated IgE, IL-4 and IL-13 levels and eosinophilia in the plasma and BALF, and mucus overproduction in the lung tissues in an OVA-induced asthmatic mouse model. Therefore, it can be used as the therapeutics or functional health food for treating and preventing inflammatory, allergic and asthmatic disease.

公开(公告)号：US09078912B2

公开(公告)日：2015-07-14

申请号：US13807829

申请日：2011-07-01

Applicant: Hyeong Kyu Lee ,  Kyung Seop Ahn ,  Yoosik Yoon ,  Byoung Whui Choi ,  Ok-Kyoung Kwon ,  Semi Kim ,  Hui Seong Kim ,  Sei Ryang Oh ,  Ji Eun Yuk ,  Ha Young Jang

Inventor： Hyeong Kyu Lee ,  Kyung Seop Ahn ,  Yoosik Yoon ,  Byoung Whui Choi ,  Ok-Kyoung Kwon ,  Semi Kim ,  Hui Seong Kim ,  Sei Ryang Oh ,  Ji Eun Yuk ,  Ha Young Jang

IPC: A61K39/395 ,  C12N15/11 ,  A61K31/7088 ,  C07K14/71 ,  C12Q1/68

CPC classification number: A61K31/7088 ,  A61K39/3955 ,  C07K14/71 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N2800/122 ,  G01N2800/24

Abstract: The present invention relates to a kit for the diagnosis or screening of asthma comprising neuropilin (NRP) gene, and to a method for screening a therapeutic agent for asthma using the same. More precisely, the present invention confirmed that NRP1 expression was increased in asthma patients and by D. pteronissinus extract. Based on the confirmation, the inventors confirmed that NRP1 could be effectively used as a target for the development of a therapeutic agent for asthma since the suppression of NRP1 expression resulted in the decrease of mRNA, protein, enzyme activity, and promoter activity of MMP-9 in relation to asthma.

Abstract translation: 本发明涉及用于诊断或筛选包含神经纤维蛋白（NRP）基因的哮喘的试剂盒，以及用于使用该试剂筛选哮喘治疗剂的方法。 更准确地说，本发明证实了哮喘患者和天竺葵提取物中NRP1的表达增加。 基于确认，本发明人证实，NRP1可以有效地用作哮喘治疗剂的发展的靶标，因为抑制NRP1表达导致mRNA，蛋白质，酶活性和启动子活性降低，MMP- 9关于哮喘。

公开(公告)号：US08883226B2

公开(公告)日：2014-11-11

申请号：US13985533

申请日：2012-02-07

Applicant: Sei Ryang Oh ,  Kyung Seop Ahn ,  Ok-Kyoung Kwon ,  Hyeong Kyu Lee ,  Joongku Lee ,  Hyouk Joung ,  Mee-Young Lee ,  Hwa-Young Son ,  Kyoung-youl Lee ,  Sang Woo Lee ,  Hang Jin ,  Wan Yi Li

Inventor： Sei Ryang Oh ,  Kyung Seop Ahn ,  Ok-Kyoung Kwon ,  Hyeong Kyu Lee ,  Joongku Lee ,  Hyouk Joung ,  Mee-Young Lee ,  Hwa-Young Son ,  Kyoung-youl Lee ,  Sang Woo Lee ,  Hang Jin ,  Wan Yi Li

IPC: A61K36/31

CPC classification number: A61K36/61

Abstract: A pharmaceutical composition for the prevention and treatment of inflammatory disease or asthma comprising the extract of Decaspermum fruticosum as an active ingredient. The extract of Decaspermum fruticosum of the present invention inhibited the increase of eosinophils in bronchoalveolar lavage fluid of the ovalbumin induced asthma animal model, had the activity of inhibiting the secretions of immunoglobulin and chemokine (Eotaxin) in bronchoalveolar lavage fluid and blood, and inhibited the secretions of NO and TNF-α in macrophages. Therefore, the extract of Decaspermum fruticosum of the present invention can be effectively used as an active ingredient of a pharmaceutical composition for the prevention and treatment of inflammatory disease or asthma, and of a health functional food for the prevention and improvement of inflammatory disease or asthma.

Abstract translation: 一种用于预防和治疗炎症性疾病或哮喘的药物组合物，其包含作为活性成分的Dececpermum fruticosum的提取物。 本发明的Decaspermum fruticosum的提取物抑制卵清蛋白诱导的哮喘动物模型的支气管肺泡灌洗液中嗜酸性粒细胞的增加，具有抑制支气管肺泡灌洗液和血液中免疫球蛋白和趋化因子（Eotaxin）分泌的活性，并抑制 巨噬细胞中NO和TNF-α的分泌。 因此，本发明的Decaspermum fruticosum的提取物可以有效地用作预防和治疗炎性疾病或哮喘的药物组合物的活性成分，以及用于预防和改善炎性疾病或哮喘的健康功能食品 。

公开(公告)号：US20130244959A1

公开(公告)日：2013-09-19

申请号：US13885986

申请日：2011-11-17

Applicant: Kyung Seop Ahn ,  Ha Young Jang ,  Sei Ryang Oh ,  Hyeong Kyu Lee ,  Ok-Kyoung Kwon ,  Semi Kim ,  Jung Hee Kim ,  Doo-Young Kim

Inventor： Kyung Seop Ahn ,  Ha Young Jang ,  Sei Ryang Oh ,  Hyeong Kyu Lee ,  Ok-Kyoung Kwon ,  Semi Kim ,  Jung Hee Kim ,  Doo-Young Kim

IPC: A61K31/7048 ,  A61K31/343

CPC classification number: A61K31/7048 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/343 ,  A61K36/185 ,  A23V2200/314 ,  A23V2250/21 ,  A23V2250/2116

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of Styrax japonica, and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-β1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed.

Abstract translation: 本发明涉及一种用于预防或治疗哮喘的药物组合物，该组合物含有作为活性成分的苯达洛尔苷A或其糖苷配基。 更特别的是，辛伐利精A化合物是从Styrax japonica的茎和吠声分离出来的化合物，作为styraxlignolide A的糖苷配基的styraxlignolide A或homoegonol，具有改善的安全性，具有减轻体重减轻和气道高反应性的作用， 的气道中的活性氧，抑制血清和支气管肺泡灌洗液中IgE，TGF-β1和IL-17的产生，抑制支气管炎性细胞浸润，抑制哮喘诱发的粘液栓塞和上皮下纤维化形成 鼠标模型。 因此，可以有效地使用辛伐利汀或同型异黄酮作为预防或治疗气道重塑进行的支气管哮喘的药物组合物的活性成分。

公开(公告)号：US20130164395A1

公开(公告)日：2013-06-27

申请号：US13820474

申请日：2011-08-30

Applicant: Kyung Seop Ahn ,  Ok-Kyoung Kwon ,  Sei Ryang Oh ,  Jung Hee Kim ,  Hyeong Kyu Lee ,  Mee-Young Lee ,  Hwa-Young Son ,  Kyoung-Youl Lee ,  Soo Yong Kim ,  Giselle Tomayo-Castillo ,  Katia Rosales-Ovares ,  Rodrigo Gamez-Lobo

Inventor： Kyung Seop Ahn ,  Ok-Kyoung Kwon ,  Sei Ryang Oh ,  Jung Hee Kim ,  Hyeong Kyu Lee ,  Mee-Young Lee ,  Hwa-Young Son ,  Kyoung-Youl Lee ,  Soo Yong Kim ,  Giselle Tomayo-Castillo ,  Katia Rosales-Ovares ,  Rodrigo Gamez-Lobo

IPC: A61K36/44

CPC classification number: A61K36/44

Abstract: Disclosed is a pharmaceutical composition for the prophylaxis and therapy of inflammatory diseases, allergic diseases, or asthma, comprising a velvet apple (Diospyros blancoi A. DC.) extract as an active ingredient. Having the inhibitory activity against the nuclear translocation of NF-κB, whose level is rapidly elevated in response to inflammatory stimuli, the velvet apple extract can suppress the production of NO and PGE2, the expression of iNOS and COX-2, and the release of IL-1β and TNF-α, and can significantly down regulate Th2-mediated IL-4 and IL-13 production. In addition, the extract was found to inhibit the activation of eosinophils in bronchoalveolar lavage fluid, and to suppress the secretion of immunoglobulins and chemokines in bronchoalveolar lavage fluid and blood, as measured by in vivo tests on an ovalbumin-induced asthma mouse model. Therefore, the extract can be used in the method for preventing or treating various inflammatory disorders, allergic diseases, or asthma.

Abstract translation: 公开了一种用于预防和治疗炎性疾病，过敏性疾病或哮喘的药物组合物，其包含天鹅绒苹果（Diospyros blancoi A.DC。）提取物作为活性成分。 天鹅绒苹果提取物对NF-κB的核易位具有抑制作用，NF-κB的水平随着炎症刺激而迅速升高，可抑制NO和PGE2的产生，iNOS和COX-2的表达，以及释放 IL-1β和TNF-α，并能显着下调Th2介导的IL-4和IL-13产生。 此外，发现提取物抑制支气管肺泡灌洗液中嗜酸性粒细胞的活化，并且通过卵清蛋白诱导的哮喘小鼠模型的体内试验测量，抑制支气管肺泡灌洗液和血液中免疫球蛋白和趋化因子的分泌。 因此，提取物可用于预防或治疗各种炎性疾病，过敏性疾病或哮喘的方法。

公开(公告)号：US20130108652A1

公开(公告)日：2013-05-02

申请号：US13807829

申请日：2011-07-01

Applicant: Hyeong Kyu Lee ,  Kyung Seop Ahn ,  Yoosik Yoon ,  Byoung Whui Choi ,  Ok-Kyoung Kwon ,  Semi Kim ,  Hui Seong Kim ,  Sei Ryang Oh ,  Ji Eun Yuk ,  Ha Young Jang

Inventor： Hyeong Kyu Lee ,  Kyung Seop Ahn ,  Yoosik Yoon ,  Byoung Whui Choi ,  Ok-Kyoung Kwon ,  Semi Kim ,  Hui Seong Kim ,  Sei Ryang Oh ,  Ji Eun Yuk ,  Ha Young Jang

IPC: A61K31/7088 ,  A61K39/395

CPC classification number: A61K31/7088 ,  A61K39/3955 ,  C07K14/71 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N2800/122 ,  G01N2800/24

Abstract: The present invention relates to a kit for the diagnosis or screening of asthma comprising neuropilin (NRP) gene, and to a method for screening a therapeutic agent for asthma using the same. More precisely, the present invention confirmed that NRP1 expression was increased in asthma patients and by D. pteronissinus extract. Based on the confirmation, the inventors confirmed that NRP1 could be effectively used as a target for the development of a therapeutic agent for asthma since the suppression of NRP1 expression resulted in the decrease of mRNA, protein, enzyme activity, and promoter activity of MMP-9 in relation to asthma.

Abstract translation: 本发明涉及用于诊断或筛选包含神经纤维蛋白（NRP）基因的哮喘的试剂盒，以及用于使用该试剂筛选哮喘治疗剂的方法。 更准确地说，本发明证实了哮喘患者和天竺葵提取物中NRP1的表达增加。 基于确认，本发明人证实，NRP1可以有效地用作哮喘治疗剂的发展的靶标，因为抑制NRP1表达导致mRNA，蛋白质，酶活性和启动子活性降低，MMP- 9关于哮喘。

公开(公告)号：US20090324750A1

公开(公告)日：2009-12-31

申请号：US11916216

申请日：2006-05-30

Applicant: Hyeong Kyu Lee ,  Sei Ryang Oh ,  Kyung Seop Ahn ,  Sang Ku Lee ,  Joong Ku Lee ,  Ok Kyoung Kwon ,  Doo Young Kim ,  Hyouk Joung ,  Gui Hua Quan ,  Mi Jin Kim ,  Bo Young Park

Inventor： Hyeong Kyu Lee ,  Sei Ryang Oh ,  Kyung Seop Ahn ,  Sang Ku Lee ,  Joong Ku Lee ,  Ok Kyoung Kwon ,  Doo Young Kim ,  Hyouk Joung ,  Gui Hua Quan ,  Mi Jin Kim ,  Bo Young Park

IPC: A61K36/68 ,  A61K31/35 ,  A61P3/02

CPC classification number: A61K36/185 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/35 ,  A61K31/352 ,  A61K36/68 ,  A61K36/80 ,  C07H17/04 ,  A23V2250/21 ,  A23V2200/324 ,  A23V2200/304

Abstract: The present invention relates to a composition comprising an extract of Pseudolysimachion genus plant, and the catalpol derivatives isolated therefrom having anti-inflammatory, antiallergic and anti-asthmatic activity. The extract of Pseudolysimachion genus plant and the catalpol derivatives isolated therefrom shows potent suppressing effect on elevated IgE, IL-4 and IL-13 levels and cosinophilia in the plasma and BALF, and mucus overproduction in the lung tissues in an OVA-induced asthmatic mouse model. Therefore, it can be used as the therapeutics or functional health food for treating and preventing inflammatory, allergic and asthmatic disease.

Abstract translation: 本发明涉及包含假单胞菌属植物提取物和从其分离的具有抗炎，抗过敏和抗哮喘活性的梓醇衍生物的组合物。 假单胞菌属植物的提取物和从其中分离的梓醇衍生物显示出对OVA诱导的哮喘小鼠肺组织中升高的IgE，IL-4和IL-13水平和血浆和BALF中的嗜酸性粒细胞增多和粘液过度产生的有效抑制作用 模型。 因此，它可以用作用于治疗和预防炎性，过敏性和哮喘性疾病的治疗剂或功能性保健食品。

公开(公告)号：US07534456B2

公开(公告)日：2009-05-19

申请号：US11802527

申请日：2007-05-23

Applicant: Hyeong Kyu Lee ,  Sei Ryang Oh ,  Kyung Seop Ahn ,  Soon Ja Choi ,  Jung Hee Kim ,  Goo Taeg Oh ,  Jung Joo Hong ,  Seong Kyu Park ,  Woo Namkung

Inventor： Hyeong Kyu Lee ,  Sei Ryang Oh ,  Kyung Seop Ahn ,  Soon Ja Choi ,  Jung Hee Kim ,  Goo Taeg Oh ,  Jung Joo Hong ,  Seong Kyu Park ,  Woo Namkung

IPC: A01N65/00

CPC classification number: A61K36/532 ,  A23L33/105 ,  A23L33/11

Abstract: This invention includes a composition of Agastache rugosa and tilianin obtained by separation-purification for anti-inflammation and anti-atherosclerosis, and more particularly, an extract of Agastache rugosa and tilianin obtained therefrom by separation-purification which are effective in preventing and treating not only inflammatory diseases but also atherosclerosis related to inflammatory responses and disease in the circulatory system caused by atherosclerosis because they are excellent in inhibiting the activity of complement systems as a factor of inflammatory responses, the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecular-1 (VCAM-1), and the production of nitric oxide (NO). They can also significantly reduce the development of atherosclerosis due to the inflammatory response.

Abstract translation: 本发明包括通过用于抗炎和抗动脉粥样硬化的分离纯化获得的藿香粗提物和斜霉素的组合物，更具体地，通过分离纯化从其获得的藿香提取物和斜霉素提取物，其不仅有效预防和治疗 炎症性疾病，而且与由动脉粥样硬化引起的循环系统中的炎性反应和疾病有关的动脉粥样硬化，因为它们作为炎症反应因子抑制补体系统的活性，细胞间粘附分子-1（ICAM-1）和 血管细胞粘附分子-1（VCAM-1）和一氧化氮（NO）的产生。 它们还可以显着减少由于炎症反应引起的动脉粥样硬化的发展。